Free Trial
ASX:BDX

BCAL Diagnostics (BDX) Stock Price, News & Analysis

BCAL Diagnostics logo

About BCAL Diagnostics Stock (ASX:BDX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$36.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BCAL Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

BDX Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

BDX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that BCAL Diagnostics investors own include Chevron (CVX), JPMorgan Chase & Co. (JPM), Bristol-Myers Squibb (BMY), 3M (MMM), NextEra Energy (NEE), ONEOK (OKE) and Tesla (TSLA).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
Medical Equipment
Current Symbol
ASX:BDX
CIK
N/A
Fax
N/A
Employees
77,000
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,400,000.00
Net Margins
-295.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.10 million
Price / Cash Flow
N/A
Book Value
A$0.03 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$36.60 million
Optionable
Not Optionable
Beta
0.69
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (ASX:BDX) was last updated on 5/10/2025 by MarketBeat.com Staff
From Our Partners